New Drug Class Targets Resistant High Blood Pressure When Standard Treatments Fail

What Is Resistant Hypertension and Why Is It So Difficult to Treat?

Resistant hypertension represents one of the most challenging problems in cardiovascular medicine. According to the American Heart Association, approximately 10 to 20 percent of patients with high blood pressure meet the criteria for treatment-resistant disease, meaning their blood pressure stays elevated despite taking three or more medications from different drug classes. These patients face significantly higher risks of heart attack, stroke, kidney failure, and death compared to those whose blood pressure responds to standard therapy.

Traditional treatment strategies for resistant hypertension have relied on adding a fourth or fifth drug — often spironolactone, a mineralocorticoid receptor antagonist — or investigating secondary causes such as renal artery stenosis or aldosterone-producing tumors. However, many patients still fail to reach their blood pressure targets, leaving clinicians with limited options. This treatment gap has driven research into entirely new biological pathways, including the endothelin system, which plays a critical role in regulating vascular tone and blood pressure.

How Does Aprocitentan Work Differently From Existing Blood Pressure Drugs?

Endothelin-1 is one of the most potent vasoconstrictors produced by the human body. In patients with resistant hypertension, the endothelin system is often overactivated, contributing to sustained arterial stiffness and elevated blood pressure that standard medications cannot fully address. Aprocitentan (marketed as Tryvio) is a dual endothelin receptor antagonist that blocks both ETA and ETB receptors, counteracting this vasoconstrictive drive at its source.

The pivotal PRECISION trial, published in The Lancet in 2023, demonstrated that aprocitentan significantly reduced systolic blood pressure compared to placebo in patients with resistant hypertension who were already on three antihypertensive agents. The drug's mechanism of action is fundamentally different from existing drug classes — ACE inhibitors, ARBs, calcium channel blockers, and diuretics — making it a genuine addition to the therapeutic arsenal rather than a variation on an existing approach. Importantly, the endothelin pathway had long been recognized in pulmonary arterial hypertension treatment, but aprocitentan is the first drug to successfully harness this mechanism for systemic resistant hypertension.

What Should Patients With Uncontrolled Blood Pressure Know?

For patients living with resistant hypertension, the expansion of treatment options represents meaningful progress. The World Health Organization estimates that 1.28 billion adults worldwide live with hypertension, and uncontrolled blood pressure remains a leading contributor to global cardiovascular mortality. Even a modest reduction in systolic blood pressure — on the order of 5 to 10 mmHg — has been shown to meaningfully reduce stroke and heart attack risk in large population studies.

Clinicians recommend that patients with persistently elevated blood pressure first ensure they are taking their current medications consistently, as non-adherence accounts for a significant portion of apparent treatment resistance. Beyond medication compliance, evaluation for secondary causes such as obstructive sleep apnea, primary aldosteronism, and chronic kidney disease can uncover treatable conditions. When true resistant hypertension is confirmed, the addition of newer agents like aprocitentan or approaches such as renal denervation may be discussed. Patients should work closely with their healthcare team, ideally including a hypertension specialist, to explore all available options.